Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.51 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.49 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.49 |
| ▸ | GABRP | O00591 | 2/20 | 0.49 |
| ▸ | GABRD | O14764 | 2/20 | 0.49 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.49 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.49 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.49 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.49 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.49 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.49 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.49 |
| ▸ | GABRE | P78334 | 2/20 | 0.49 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.49 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.49 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8807647 | 0.97 | ADORA1 (0.94) | ADORA1KDM4EHSD17B10TSHRMAPK1 | |
| SCHEMBL8807266 | 0.94 | ADORA1 (0.88) | ADORA1KDM4EHSD17B10TSHRMAPK1 | |
| SCHEMBL19829272 | 0.93 | ADORA1 (0.86) | ADORA1KDM4EHSD17B10TSHRMAPK1 | |
| SCHEMBL8808692 | 0.89 | ADORA1 (0.80) | ADORA1KDM4EHSD17B10MAPK1IGF1R | |
| SCHEMBL7294123 | 0.88 | ADORA1 (0.79) | ADORA1KDM4EMAPK1IGF1RHTT | |
| SCHEMBL9585781 | 0.88 | ADORA1 (0.78) | ADORA1KDM4EHSD17B10TSHRMAPK1 | |
| SCHEMBL8808149 | 0.87 | ADORA1 (0.77) | ADORA1KDM4EHSD17B10MAPK1IGF1R | |
| SCHEMBL8807841 | 0.87 | ADORA1 (0.77) | ADORA1KDM4EHSD17B10TSHRMAPK1 | |
| SCHEMBL7299166 | 0.87 | ADORA1 (0.77) | ADORA1KDM4ETSHRMAPK1IGF1R | |
| SCHEMBL7291837 | 0.87 | ADORA1 (0.76) | ADORA1KDM4EHSD17B10MAPK1IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1429775-A4 | METHODS OF TREATING PULMONARY DISEASE | BIOGEN IDEC INC (US) | 2007-04-11 | — | — | EP | claimed |
| EP-1084710-B1 | ADENOSINE A1 ANTAGONISTS FOR MALE STERILITY | ASTELLAS PHARMA INC (JP) | 2006-10-18 | — | — | EP | claimed |
| US-20040259889-A1 | Methods of treating pulmonary disease | BIOGEN IDEC MA INC. | 2004-12-23 | — | — | US | claimed |
| EP-0900796-B1 | PREVENTIVES AND REMEDIES FOR ISCHEMIC INTESTINAL LESION AND ILEUS | FUJISAWA PHARMACEUTICAL CO (JP) | 2004-12-15 | — | — | EP | claimed |
| EP-1429775-A1 | METHODS OF TREATING PULMONARY DISEASE | Biogen Idec MA Inc. (US) | 2004-06-23 | — | — | EP | claimed |
| WO-2003022284-A1 | METHODS OF TREATING PULMONARY DISEASE | BIOGEN IDEC MA INC. (US) | 2003-03-20 | — | — | WO | claimed |
| US-6521656-B1 | Contacting sperm with a pyrazolo(1,5-a)pyridine acrosomal reaction induction promoter then joining with ovum | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-02-18 | — | — | US | claimed |
| EP-0497258-B1 | Use of adenosine antagonists in the prevention and treatment of pancreatitis and ulcer | FUJISAWA PHARMACEUTICAL CO (JP) | 2002-01-02 | — | — | EP | claimed |
| US-6303624-B1 | PREVENTION AND/OR TREATMENT OF HYPERPHOSPHATEMIA OR SECONDARY HYPERPARATHYROIDISM, INCLUSIVE OF ACCESSORY DISORDERS BY ADMINISTERING A PHARMACEUTICAL COMPOSITION WHICH COMPRISES AN ADENOSINE ANTAGONIST COMPOUND OR ITS SALT | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-10-16 | — | — | US | claimed |
| US-6232324-B1 | AS HYPERTENSIVE AGENTS FOR DIALYSIS INDUCED HYPOTENSION; ADMINISTERING COMPOUNDS SUCH AS 1-(3-(2-PHENYLPYRAZOLO(1,5-A) PYRIDIN-3-YL)ACRYLOYL)-2-(CARBOXY METHYL)PIPERIDINE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-05-15 | — | — | US | claimed |
| EP-0970696-A1 | Combination of loop diuretics with adenosine A1-receptor antagonists | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2000-01-12 | — | — | EP | claimed |
| EP-0900796-A1 | PREVENTIVES AND REMEDIES FOR ISCHEMIC INTESTINAL LESION AND ILEUS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-03-10 | — | — | EP | claimed |
| EP-0644762-B1 | PYRAZOLOPYRIDINE COMPOUNDS FOR THE TREATMENT OF ANEMIA | FUJISAWA PHARMACEUTICAL CO (JP) | 1997-12-17 | — | — | EP | claimed |
| US-5643938-A | RAISING THE ERYTHROPOIETIN LEVEL IN HUMANS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-07-01 | — | — | US | claimed |
| EP-0379979-B1 | Pyrazolopyridine compounds and processes for preparation thereof | FUJISAWA PHARMACEUTICAL CO (JP) | 1997-03-19 | — | — | EP | claimed |
| JP-H08500338-A | — | — | 1996-01-16 | — | — | JP | claimed |
| EP-0644762-A1 | PYRAZOLOPYRIDINE COMPOUNDS FOR THE TREATMENT OF ANEMIA | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-03-29 | — | — | EP | claimed |
| WO-1993025205-A1 | PYRAZOLOPYRIDINE COMPOUNDS FOR THE TREATMENT OF ANEMIA | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-12-23 | — | — | WO | claimed |
| US-4985444-A | Pyrazolopyridine compound and processes for preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-01-15 | — | — | US | claimed |
| EP-0379979-A1 | Pyrazolopyridine compounds and processes for preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1990-08-01 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259889-A1 | Methods of treating pulmonary disease | ADORA1, ADORA2A, TBXA2R | ADORA1 1/4885KDM4E 4124/4885HSD17B10 2509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.